En Es

Industry News

Global Automated Breast Ultrasound Systems Market to Surpass USD 1.8 Billion by 2025

By Medimaging International staff writers
07 Nov 2019

Image: The global automated breast ultrasound systems (ABUS) market is being driven by increasing government expenditure and rising awareness about breast cancer (Photo courtesy of Philips Healthcare).The global automated breast ultrasound systems (ABUS) market was valued at over USD 0.68 billion in 2018 and is projected to grow at a CAGR 16.1% during the forecast period, 2019-2025 to surpass USD 1.8 billion by 2025, driven by increasing government expenditure and rising awareness about breast cancer. Initiatives such as free check-up camps and symposiums for raising awareness regarding early detection and diagnosis of breast cancer will lead to greater adoption of ABUS in the coming years. However, stringent regulations and guidelines for the approval of ABUS, coupled with the high cost of diagnostic procedure, could hamper the market growth during the forecast period.

These are the latest findings of Global Market Insights, Inc. (Selbyville, DE, USA; www.gminsights.com), a global market research and management consulting company.

ABUS is superior than conventional technologies in the detection of consistent breast lesion growth. ABUS assists during critical processes for identification and characterization of breast lesions, leading to reduced treatment costs. Moreover, ABUS provide precise anatomical images for breast cancer diagnosis, thereby majorly impacting operational and diagnostic efficiency. Increasing advancements in ABUS for accurate diagnosis and timely treatment will increase the adoption of breast ultrasound systems over the coming years.

High breast tissue density, lower childbearing and hormonal imbalance issues among women due to changing lifestyle are the major risk factors for breast cancer, thus providing lucrative opportunities for the growth of the global ABUS market. According to the World Health Organization, approximately 2.1 million patients suffer from breast cancer each year. The rising prevalence of breast cancer globally will generate significant demand for ABUS over the forecast period.

In 2018, the diagnostic imaging centers segment reported revenues of USD 0.65 billion. The adoption of ABUS in diagnostic imaging centers is estimated to witness rapid growth due to the expansion of early diagnosis and detection of cancerous cells in the body. The growing availability of specialized technology-based breast imaging techniques and cutting-edge imaging technologies in diagnostic facilities will augment the growth of the diagnostic imaging centers segment. Furthermore, the increasing number of facilities and healthcare infrastructure in the emerging countries will drive the segmental growth during the forecast period.

Geographically, the US held a share of more than 89.0% in the global ABUS market in 2018. The growing adoption of ABUS for the early detection of breast cancer, coupled with the implementation of government initiatives such as Pink Initiative, funding as well as increased awareness will act as the key drivers of the market growth in the US. Furthermore, the presence of established market players in the US will contribute significantly to the growth of the country’s ABUS market during the forecast period.

The ABUS market in Saudi Arabia is projected to grow at a lucrative CAGR of 20.1% during the forecast period, driven by rapidly emerging cancer diagnosis and treatment in the country. Increasing hospitals and government expenditure offering cost advantages are driving the adoption rate of ABUS in Saudi Arabia. Moreover, an increasing patient pool along with growing research activities for innovating ABUS will further aid the growth of the ABUS market in Saudi Arabia.

Related Links:
Global Market Insights, Inc.

E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

03 Aug 2020
Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio
Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with a comprehensive portfolio to fight cancer.
Read More
17 Jul 2020
Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years
Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer for the detection of syphilis.
Read More
23 Jun 2020
Omnia Health Live Unites Global Healthcare Community Through New Virtual Experience
Omnia Health Live, a virtual healthcare event, has brought the global healthcare community together on a scale never seen before through a new experience delivered entirely online.
Read More
12 Jun 2020
Global Magnetic Resonance Imaging (MRI) Market to be driven by Advancements in Medical Diagnostics
The global magnetic resonance imaging (MRI) market was valued at USD 5.90 billion in 2017 and is projected to register a CAGR of 5.2% from 2018 to 2026, driven by increased demand for MRI equipment across the world due to a substantial rise in incidence of disorders related to spine, neurology, orthopedic, cardiovascular, head and neck, and abdominal and prostate.
Read More
30 May 2020
MEDICAL FAIR ASIA 2020 Set to Take Place in Singapore from 9-11 December 2020
MEDICAL FAIR ASIA 2020 is set to take place in Singapore from 9-11 December 2020 at Marina Bay Sands, with the exhibition featuring the latest medical technology and innovations, and healthcare equipment and supplies.
Read More
20 Apr 2020
Nova's Stat EMS Basic Blood Testing System Launched in CE Mark Countries
Nova Biomedical (Waltham, MA, USA) has launched the Stat EMS Basic blood testing system for ambulance and emergency care in CE mark countries. Stat EMS Basic measures fingerstick capillary lactate, glucose, ketone, hemoglobin, and hematocrit in six to 40 seconds with laboratory-quality results.
Read More
20 Apr 2020
Nova's Stat Profile Prime Plus Blood Gas Analyzer Receives FDA Clearance for POC Use
Nova Biomedical (Waltham, MA, USA) has secured clearance from the US Food and Drug Administration (FDA) for its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care (POC) use.
Read More
17 Apr 2020
ECR 2020 to Go Ahead as Online Congress on July 15-19, 2020
In view of the ongoing spread of COVID-19 across the world and its growing global impact, the board of directors of the European Society of Radiology (Vienna) has decided not to hold an onsite European Congress of Radiology (ECR) in 2020. Instead, ECR 2020 will go ahead as an online congress to ensure a safe experience for its members, partners, staff and the general public.
Read More
08 Apr 2020
Nova Biomedical Adds PT/INR Test to Allegro Analyzer for POC Testing
Nova Biomedical (Waltham, MA, USA) has added PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. With the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the POC.
Read More
Copyright © 2000-2020 TradeMed.com. All rights reserved. | Terms And Conditions